Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

Trial Profile

Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Primary hyperparathyroidism
  • Focus Therapeutic Use
  • Acronyms EPATH
  • Most Recent Events

    • 24 Sep 2017 Last checked against ISRCTN: Current Controlled Trials record.
    • 20 Aug 2017 Results of cross-sectional relationship between parathyroid hormone and cardiovascular parameters (n=76) published in the Journal of Clinical Hypertension (Greenwich)
    • 27 Jun 2017 Results published in the Clinical Chemistry and Laboratory Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top